RANOLAZINE

-
Dosing Information
Adult: In Angina pectoris, chronic, initial, 500 mg orally twice daily; increase to the maximum recommended dose of 1000 mg orally twice daily as needed based on clinical symptoms.
Pediatric: Safety and efficacy not established in pediatric patients.
Contraindications
• Concurrent use of potent and moderately potent CYP3A inhibitors, including diltiazem, verapamil, macrolide antibiotics, HIV protease inhibitors, ketoconazole and other azole antifungals, and grapefruit juice or grapefruit-containing products; increased ranolazine levels and QTc prolongation.
• Concurrent use of QT prolonging drugs (such as Class Ia and Class III antiarrhythmics, and certain antipsychotic).
• Hepatic impairment, Child-Pugh Classes A, B or C; QTc prolongation is increased approximately 3-fold.
• QT prolongation, pre-existing, including congenital long QT syndrome and uncorrected hypokalemia.
Precautions
• Concurrent use of CYP3A and P-glycoprotein inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentin, St John’s Wort) should be avoided; decreased ranolazine concentrations.
• Doses greater than 1,000 mg twice daily should be avoided; increased risk of QTc interval prolongation.
• QTc interval prolongation; dose-related prolongation may occur, possibly leading to torsades de pointes-type arrhythmias and sudden death.
• Renal impairment, severe; increases blood pressure by approximately 15 mmHg.
• Ventricular tachycardia, history.
Adverse Effects
• Prolonged QT interval
• Serum blood urea nitrogen raised
• Syncope
Pharmacokinetics
Onset and Duration of action: Initial Response in stable angina, Oral: 2.5 hours (single doses; reflects time of efficacy measurements after dosing).

Drug Concentration Levels
A) Therapeutic Drug Concentration: In stable Angina Pectoris 500 ng/mL suggested in single-dose study.
B) Peak Concentration
1) Oral, extended-release: 2569 ng/mL.
2) Steady state peak and trough plasma concentrations for ranolazine and its metabolites were generally higher in renally impaired subjects compared to healthy subjects. Patients received a ranolazine extended-release loading dose of 875 mg orally, followed by 500 mg every 12 hours for a total of 4 maintenance doses.
C) Time to Peak Concentration: Oral, extended-release: 2 to 5 hours.

Mechanism of Action
1) Ranolazine is a piperazine derivative and the mechanism of action of its anti-anginal and anti-ischemic effect is unknown. The anti-anginal and anti-ischemic action of ranolazine is not dependent upon heart rate or blood pressure reduction and does not increase myocardial workload. At therapeutic levels, ranolazine can inhibit the inactivating component of the sodium current (I(Na)) although its relationship to angina symptoms is uncertain. It also inhibits the rapid inward rectifying current (I(Kr)), thereby prolonging the ventricular action potential.
2) Ranolazine has also been postulated to modulate myocardial metabolism by partially inhibiting fatty acid oxidation, thereby increasing glucose oxidation and generating more adenosine triphosphate (ATP) per molecule of oxygen consumed (i.e., cardiac muscle cell substrate utilization is shifted towards carbohydrates and away from fatty acids). The anti-anginal and anti-ischemic action of ranolazine is not dependent upon heart rate or blood pressure reduction and does not increase myocardial workload.
3) Action unlike beta-blockers and calcium antagonists, ranolazine lacks effects on hemodynamics, contractile/ conduction parameters.
4) Ranolazine has renal transplant preservation potential.

Comments

Post a Comment

Popular posts from this blog

Treatment Guidelines for Malaria Contd...

-
Treatment regimens for uncomplicated malaria in adults _ Oral quinine sulphate 600 mg/8 h for 5e7 days plus doxycycline 200 mg daily (or clindamycin 450 mg/8 h for pregnant women) for 7 days _ Atovaquoneeproguanil (Malarone_): 4 ‘standard’ tablets daily for 3 days or _ Co-artem ((artemetherelumefantrine_): if weight > 35 kg, 4 tablets  then 4 tablets at 8, 24, 36, 48 and 60 h   Child Initial dose 10 mg/kg/base then 5 mg/kg  base 6e8 h later and on days 2 and 3   However, both of these newer regimens need to be taken for only 3 days. In contrast, quinine needs to be taken for 5e7 days and is often associated with ‘‘cinchonism’’ (nausea, deafness and ringing in the ears), which often results in poor adherence. Although international recommendations suggest that quinine should be  taken for 7 days in endemic areas, 2  UK experience suggests  that 5 days treatment is adequate for the vast majority of cases. Quinine should be combined with a second drug (doxycycline for adults or clindam...
Read more

Basics of Oral Anti-diabetic drugs

-
The sulfonylureas and meglitinides increase the secretion of insulin by the pancreas. _ Metformin inhibits glucose production by the liver and decreases insulin resistance. _ The alpha-glucosidase inhibitors delay absorption of glucose by the intestine. _ The thiazolidinediones decrease insulin resistance. _ The dipeptidyl peptidase 4 inhibitors promote the release of insulin from the pancreas after eating a meal. It is  necessary  to know before starting these drugs that  all the diabetes drugs have the potential to cause side effects and lifestyle changes have benefits to your health beyond controlling blood sugar, most doctors will recommend you try diet and lifestyle modifications first — before you try a drug. Subscribe to Drugs Information Center by Email
Read more

Ranexa

-
Ranexa is an anti-anginal medication. It works by improving blood flow to help the heart work more efficiently. Ranexa is used to chronic treat angina (chronic chest pain) when other medications have not helped the condition. It should be used in combination with another medicine (eg, amlodipine, beta-blockers, nitrates). You should not take Ranexa if you have liver disease, hypokalemia (low levels of potassium in your blood), or a personal or family history of "Long QT syndrome." Ranexa should not be taken together with certain medicines to treat heart rhythm disorders, malaria, infections, mental illness, pain, cancer, or stomach disorders. Before you take Ranexa, tell your doctor about all other medications you are using. Ranexa is not for use during an acute (emergency) attack of angina. Continue using any other medicines prescribed by your doctor (such as nitroglycerin) to treat acute angina. Chronic angina is often treated with a combination of different drugs. To best ...
Read more